Logo image of AAPG

ASCENTAGE PHARMA GR-ADR (AAPG) Stock Price, Quote, News and Overview

NASDAQ:AAPG - Nasdaq - ADR - Currency: USD

24.4257  -1.39 (-5.38%)

After market: 24.54 +0.11 (+0.47%)

AAPG Quote, Performance and Key Statistics

ASCENTAGE PHARMA GR-ADR

NASDAQ:AAPG (5/28/2025, 8:16:33 PM)

After market: 24.54 +0.11 (+0.47%)

24.4257

-1.39 (-5.38%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week HighN/A
52 Week LowN/A
Market Cap2.13B
Shares87.11M
Float61.94M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO10-28 2019-10-28


AAPG short term performance overview.The bars show the price performance of AAPG in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 5 10 15 20 25

AAPG long term performance overview.The bars show the price performance of AAPG in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of AAPG is 24.4257 USD. In the past month the price increased by 0.93%.

ASCENTAGE PHARMA GR-ADR / AAPG Daily stock chart

AAPG Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 17.83 323.41B
AMGN AMGEN INC 13.41 149.70B
GILD GILEAD SCIENCES INC 14.01 134.89B
VRTX VERTEX PHARMACEUTICALS INC N/A 114.30B
REGN REGENERON PHARMACEUTICALS 13.36 63.90B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 37.23B
ARGX ARGENX SE - ADR 98.17 35.18B
ONC BEIGENE LTD-ADR 6.15 25.99B
BNTX BIONTECH SE-ADR N/A 23.45B
NTRA NATERA INC N/A 22.01B
SMMT SUMMIT THERAPEUTICS INC N/A 19.34B
BIIB BIOGEN INC 8.06 18.69B

About AAPG

Company Profile

AAPG logo image Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. The company is headquartered in Suzhou, Jiangsu and currently employs 567 full-time employees. The company went IPO on 2019-10-28. The Company’s main business is engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus and certain age-related diseases. The Company’s main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918 and other products. The Company’s products are mainly used to address the major hematological malignancies, including chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and multiple myeloma. The firm mainly conducts its business in the domestic market.

Company Info

ASCENTAGE PHARMA GR-ADR

68 Xinqing Road, Suzhou Industrial Park

Suzhou JIANGSU CN

Employees: 567

AAPG Company Website

AAPG Investor Relations

ASCENTAGE PHARMA GR-ADR / AAPG FAQ

What is the stock price of ASCENTAGE PHARMA GR-ADR today?

The current stock price of AAPG is 24.4257 USD. The price decreased by -5.38% in the last trading session.


What is the ticker symbol for ASCENTAGE PHARMA GR-ADR stock?

The exchange symbol of ASCENTAGE PHARMA GR-ADR is AAPG and it is listed on the Nasdaq exchange.


On which exchange is AAPG stock listed?

AAPG stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ASCENTAGE PHARMA GR-ADR stock?

14 analysts have analysed AAPG and the average price target is 26.43 USD. This implies a price increase of 8.22% is expected in the next year compared to the current price of 24.4257. Check the ASCENTAGE PHARMA GR-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ASCENTAGE PHARMA GR-ADR worth?

ASCENTAGE PHARMA GR-ADR (AAPG) has a market capitalization of 2.13B USD. This makes AAPG a Mid Cap stock.


How many employees does ASCENTAGE PHARMA GR-ADR have?

ASCENTAGE PHARMA GR-ADR (AAPG) currently has 567 employees.


What are the support and resistance levels for ASCENTAGE PHARMA GR-ADR (AAPG) stock?

ASCENTAGE PHARMA GR-ADR (AAPG) has a support level at 24.28 and a resistance level at 26.49. Check the full technical report for a detailed analysis of AAPG support and resistance levels.


Is ASCENTAGE PHARMA GR-ADR (AAPG) expected to grow?

The Revenue of ASCENTAGE PHARMA GR-ADR (AAPG) is expected to decline by -48.7% in the next year. Check the estimates tab for more information on the AAPG EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ASCENTAGE PHARMA GR-ADR (AAPG) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ASCENTAGE PHARMA GR-ADR (AAPG) stock pay dividends?

AAPG does not pay a dividend.


What is the Price/Earnings (PE) ratio of ASCENTAGE PHARMA GR-ADR (AAPG)?

ASCENTAGE PHARMA GR-ADR (AAPG) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.63).


What is the Short Interest ratio of ASCENTAGE PHARMA GR-ADR (AAPG) stock?

The outstanding short interest for ASCENTAGE PHARMA GR-ADR (AAPG) is 0.03% of its float. Check the ownership tab for more information on the AAPG short interest.


AAPG Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to AAPG.


Chartmill TA Rating
Chartmill Setup Rating

AAPG Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to AAPG. AAPG has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

AAPG Financial Highlights

Over the last trailing twelve months AAPG reported a non-GAAP Earnings per Share(EPS) of -0.63. The EPS increased by 61.43% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -15.49%
ROE -153.46%
Debt/Equity 4.46
Chartmill High Growth Momentum
EPS Q2Q%-0.86%
Sales Q2Q%97.9%
EPS 1Y (TTM)61.43%
Revenue 1Y (TTM)341.77%

AAPG Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 87% to AAPG. The Buy consensus is the average rating of analysts ratings from 14 analysts.

For the next year, analysts expect an EPS growth of -182.73% and a revenue growth -48.7% for AAPG


Ownership
Inst Owners7.36%
Ins Owners13.63%
Short Float %0.03%
Short Ratio0.54
Analysts
Analysts87.14
Price Target26.43 (8.21%)
EPS Next Y-182.73%
Revenue Next Year-48.7%